Related Experiment Video
Updated: Aug 3, 2025
Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Resistin Contribution to Cardiovascular Risk in Chronic Kidney Disease Male Patients
Katarzyna Romejko1, Aleksandra Rymarz1, Katarzyna Szamotulska2
1Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine-National Research Institute, 04-141 Warsaw, Poland.
Insights
Resistin levels are higher in men with chronic kidney disease (CKD) and correlate with cardiovascular risk. This relationship is influenced by PAI-1 levels, suggesting resistin
Area of Science:
- Endocrinology and Metabolism
- Nephrology
- Cardiology
Background:
- Resistin, a protein in the Resistin-Like Molecules (RELMs) family, is implicated in inflammatory processes and cardiovascular complications.
- Elevated resistin concentrations are linked to atherosclerosis development and progression.
- Chronic kidney disease (CKD) is associated with increased cardiovascular (CV) risk.
Purpose of the Study:
- To investigate the association between resistin levels and cardiovascular risk in men with non-dialysis-dependent CKD.
- To explore the role of resistin in the context of CKD-related cardiovascular risk factors.
Main Methods:
- Study included 142 men: 99 with CKD (eGFR < 60 mL/min/1.73 m²) and 43 controls (eGFR ≥ 60 mL/min/1.73 m²).
- Assessed cardiovascular risk and measured serum resistin, tumor necrosis factor-alpha (TNF-alpha), and plasminogen activator inhibitor-1 (PAI-1).
Main Results:
- Resistin concentrations were significantly higher in CKD patients compared to controls (p = 0.003).
- In CKD patients, resistin was associated with increased CV risk (p = 0.026) and higher PAI-1 levels (p = 0.012).
- The association between PAI-1 and resistin was dependent on the level of CV risk in CKD patients (p = 0.048).
Conclusions:
- Resistin concentrations increase with escalating CV risk in CKD patients, potentially contributing to cardiovascular risk progression.
- The relationship between resistin and CV risk in CKD is modified by PAI-1 concentrations.
Background:
Resistin is a molecule that belongs to the Resistin-Like Molecules family (RELMs), the group of proteins taking part in inflammatory processes. Increased resistin concentrations are observed in cardiovascular complications. Resistin contributes to the onset of atherosclerosis and intensifies the atherosclerotic processes. The aim of this study was to investigate the relationship between resistin and cardiovascular (CV) risk in men with chronic kidney disease (CKD) not treated with dialysis.
Materials And Methods:
One hundred and forty-two men were included in the study: 99 men with eGFR lower than 60 mL/min/1.73 m2 and 43 men with eGFR ≥ 60 mL/min/1.73 m2. CV risk was assessed. Serum resistin, tumor necrosis factor-alpha (TNF-alpha) and plasminogen activator inhibitor-1 (PAI-1) were measured among other biochemical parameters.
Results:
We observed that resistin concentrations were significantly higher in patients with CKD compared to individuals with eGFR ≥ 60 mL/min/1.73 m2 (p = 0.003). In CKD, after estimating the general linear model (GLM), we found that resistin is associated with CV risk (p = 0.026) and PAI-1 serum concentrations (0.012). The relationship of PAI-1 with resistin depends on the level of CV risk in CKD (p = 0.048).
Conclusions:
Resistin concentrations rise with the increase of CV risk in CKD patients and thus resistin may contribute to the progression of cardiovascular risk in this group of patients. The relationship between resistin and CV risk is modified by PAI-1 concentrations.
Related Concept Videos
01:24Chronic Kidney Disease II: Clinical Manifestations
01:25Chronic Kidney Disease I: Introduction
01:28Chronic Kidney Disease III: Interprofessional Care
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:18Chronic Kidney Disease IV: Nursing Management
01:30Coronary Artery Disease I: Introduction